| 000 | 01727cam a2200337 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030726.0 | ||
| 008 | 121218s2012 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.08.08.M.Sc.2012.Do.C | ||
| 100 | 0 | _aDoaa Hussein Mobarak | |
| 245 | 1 | 0 |
_aControlled release encapsulated antibiotic for the treatment of chronic infectious diseases / _cDoaa Hussein Mobarak ; Supervised Seham A. Elkheshen , Salwa Salah Eldin |
| 246 | 1 | 5 | _aحويصلات محكمة الانطلاق لاحد مضادات البكتريا لعلاج الالتهاب المزمنة |
| 260 |
_aCairo : _bDoaa Hussein Mobarak , _c2012 |
||
| 300 |
_a183 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics | ||
| 520 | _aChronic osteomyelitis is a challenging disease and very expensive to treat besides being recurrent. Chronic osteomyelitis recurrence is now highly suggested to be related to the intracellular infection caused by the staphylococcus aureus (S.A.). Nanoparticles (NPs) offer several advantages. Ciprofloxacin (CP) is a second generation fluroquinolone antibiotic with a broad spectrum against both gram positive and gram negative bacteria | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aCiprofloxacin hydrochloride | |
| 653 | 4 | _aMicrobiological evaluation | |
| 653 | 4 | _aNanoparticles | |
| 700 | 0 |
_aSalwa Salah Eldin , _eSupervisor |
|
| 700 | 0 |
_aSeham Abdelkhalk Elkheshen , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c40635 _d40635 |
||